An Act to amend the Code of Virginia by adding a section numbered 38.2-3407.5:3, relating to health insurance; coverage for early refills of prescription eye drops.
Impact
The passage of HB 490 is expected to enhance patient care by allowing timely access to necessary medications. By ensuring that early refills of prescription eye drops are covered under health benefit plans, the bill aims to avoid situations where patients run out of their medication before a scheduled refill. This legislative change will help streamline the process for patients, potentially leading to better health outcomes, especially for those using these medications for chronic conditions.
Summary
House Bill 490 is a legislative measure aimed at amending the Code of Virginia to ensure that individuals have access to early refills of prescription eye drops under specific circumstances. The bill mandates that no health carrier can deny coverage for an early refill if the eye drops are a covered benefit and the prescriber confirms that additional quantities are medically necessary. This provision is particularly important for patients who rely on prescription eye drops for ongoing health issues, as it could potentially prevent the interruption of treatment due to refill limitations.
Sentiment
The general sentiment surrounding the bill appears to be positive, particularly among healthcare advocates and patients who will benefit from the provision. Supporters argue that this bill represents a necessary step toward improving patient accessibility to critical medications without undue financial burden. There were no recorded objections during the voting process, indicating a consensus among legislators on the importance of this measure.
Contention
While the bill received unanimous support and did not face significant opposition during debates or voting, some potential areas of contention could arise in how the definitions of 'medically necessary' are interpreted by insurers, which may affect patients' access to refills. Additionally, ensuring consistent implementation across various health plans could present challenges that stakeholders will need to address moving forward. Overall, HB 490 represents a proactive approach to addressing the needs of patients who require regular access to prescription eye drops.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.